Address
919 East Hillsdale Boulevard
Foster City, CA 94404
United States of America (the)
Phone
650 473 7700
Website
Sector
Healthcare
Industry
Biotechnology
Employees
229
First IPO Date
January 29, 2018
| Name | Title | Pay | Year Born |
| Harout Semerjian | Chief Executive Officer, President & Director | 526,355 | 1970 |
| Ahmed ElNawawi | Executive Vice President & Chief Commercial Officer | 307,934 | 1981 |
| Timothy Williams | Executive Vice President, Chief Legal Officer & Corporate Secretary | 485,317 | 1977 |
| Michelle J. Robertson | Executive Vice President, Chief Financial Officer, Treasurer and Principal Financial & Accounting Officer | 810,552 | 1967 |
| Joseph Emile Eid | Executive Vice President of Research & Development and Chief Medical Officer | 1M | 1967 |
| Dawn Schottlandt | Senior Vice President of Investor Relations & Corporate Affairs | 0 | N/A |
| Shanthakumar Tyavanagimatt | Senior Vice President & Chief Technical Officer | 0 | N/A |
| Aron Feingold | Vice President of Investor Relations & Corporate Communications | 0 | N/A |
| Shannon Odam | Executive Vice President & Chief People Officer | 0 | 1975 |
| Bryan Ridgell | Senior Vice President of Portfolio & Project Management and Chief of Staff | 0 | N/A |
Geron Corporation is an advanced-stage biopharmaceutical company specializing in the creation and market introduction of therapies for myeloid hematologic malignancies. Its principal drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical trials. This agent is designed to curb the rampant proliferation of malignant stem and progenitor cells in these blood cancers. Imetelstat is being developed for treating patients with low or intermediate-1 risk myelodysplastic syndromes, as well as those with intermediate-2 or high-risk myelofibrosis. The company was founded in 1990 and has its headquarters in Foster City, California.